ThuliumV1, PubMed, Corpus, bibRecord, 000626

Peptidyl molecular imaging contrast agents using a new solid-phase peptide synthesis approach.

Identifieur interne : 000626 ( PubMed/Corpus ); précédent : 000625; suivant : 000627

Peptidyl molecular imaging contrast agents using a new solid-phase peptide synthesis approach.

Auteurs : Byunghee Yoo ; Mark D. Pagel

Source :

Bioconjugate chemistry [ 1043-1802 ]

RBID : pubmed:17330953

English descriptors

KwdEn :
- Contrast Media (chemical synthesis), Diagnostic Imaging, Heterocyclic Compounds, 1-Ring (chemistry), Peptides (chemical synthesis), Thulium (chemistry).
MESH :
- chemical , chemical synthesis : Contrast Media, Peptides.
- chemical , chemistry : Heterocyclic Compounds, 1-Ring, Thulium.
- Diagnostic Imaging.

Abstract

A versatile method is disclosed for solid-phase peptide synthesis (SPPS) of molecular imaging contrast agents. A DO3A moiety was derivatized to introduce a CBZ-protected amino group and then coupled to a polymeric support. CBZ cleavage with Et2AlCl/thioanisole was optimized for SPPS. Amino acids were then coupled to the aminoDOTA-loaded resin using conventional stepwise Fmoc SPPS to create a product with DOTA coupled to the C-terminus of the peptide. In a second study, the DO3A moiety was coupled to a glycine-loaded polymeric support, and amino acids were then coupled to the amino-DOTA-peptide-loaded resin using SPPS to incorporate DOTA within the peptide sequence. The peptide-(Tm3+-DOTA) amide showed a paramagnetic chemical exchange saturation transfer (PARACEST) effect, which demonstrated the utility of this contrast agent for molecular imaging. These results demonstrate the advantages of exploiting SPPS methodologies through development of unique DOTA derivatives to create peptide-based molecular imaging contrast agents.

DOI: 10.1021/bc060250q
PubMed: 17330953

Links to Exploration step

pubmed:17330953

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Peptidyl molecular imaging contrast agents using a new solid-phase peptide synthesis approach.</title>
<author><name sortKey="Yoo, Byunghee" sort="Yoo, Byunghee" uniqKey="Yoo B" first="Byunghee" last="Yoo">Byunghee Yoo</name>
<affiliation><nlm:affiliation>Case Center of Imaging Research and Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio 44106, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pagel, Mark D" sort="Pagel, Mark D" uniqKey="Pagel M" first="Mark D" last="Pagel">Mark D. Pagel</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="????"><PubDate><MedlineDate>2007 May-Jun</MedlineDate>
</PubDate>
</date>
<idno type="doi">10.1021/bc060250q</idno>
<idno type="RBID">pubmed:17330953</idno>
<idno type="pmid">17330953</idno>
<idno type="wicri:Area/PubMed/Corpus">000626</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000626</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Peptidyl molecular imaging contrast agents using a new solid-phase peptide synthesis approach.</title>
<author><name sortKey="Yoo, Byunghee" sort="Yoo, Byunghee" uniqKey="Yoo B" first="Byunghee" last="Yoo">Byunghee Yoo</name>
<affiliation><nlm:affiliation>Case Center of Imaging Research and Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio 44106, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pagel, Mark D" sort="Pagel, Mark D" uniqKey="Pagel M" first="Mark D" last="Pagel">Mark D. Pagel</name>
</author>
</analytic>
<series><title level="j">Bioconjugate chemistry</title>
<idno type="ISSN">1043-1802</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Contrast Media (chemical synthesis)</term>
<term>Diagnostic Imaging</term>
<term>Heterocyclic Compounds, 1-Ring (chemistry)</term>
<term>Peptides (chemical synthesis)</term>
<term>Thulium (chemistry)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Contrast Media</term>
<term>Peptides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Heterocyclic Compounds, 1-Ring</term>
<term>Thulium</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Diagnostic Imaging</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A versatile method is disclosed for solid-phase peptide synthesis (SPPS) of molecular imaging contrast agents. A DO3A moiety was derivatized to introduce a CBZ-protected amino group and then coupled to a polymeric support. CBZ cleavage with Et2AlCl/thioanisole was optimized for SPPS. Amino acids were then coupled to the aminoDOTA-loaded resin using conventional stepwise Fmoc SPPS to create a product with DOTA coupled to the C-terminus of the peptide. In a second study, the DO3A moiety was coupled to a glycine-loaded polymeric support, and amino acids were then coupled to the amino-DOTA-peptide-loaded resin using SPPS to incorporate DOTA within the peptide sequence. The peptide-(Tm3+-DOTA) amide showed a paramagnetic chemical exchange saturation transfer (PARACEST) effect, which demonstrated the utility of this contrast agent for molecular imaging. These results demonstrate the advantages of exploiting SPPS methodologies through development of unique DOTA derivatives to create peptide-based molecular imaging contrast agents.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17330953</PMID>
<DateCreated><Year>2007</Year>
<Month>05</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted><Year>2007</Year>
<Month>08</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised><Year>2014</Year>
<Month>09</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1043-1802</ISSN>
<JournalIssue CitedMedium="Print"><Volume>18</Volume>
<Issue>3</Issue>
<PubDate><MedlineDate>2007 May-Jun</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Bioconjugate chemistry</Title>
<ISOAbbreviation>Bioconjug. Chem.</ISOAbbreviation>
</Journal>
<ArticleTitle>Peptidyl molecular imaging contrast agents using a new solid-phase peptide synthesis approach.</ArticleTitle>
<Pagination><MedlinePgn>903-11</MedlinePgn>
</Pagination>
<Abstract><AbstractText>A versatile method is disclosed for solid-phase peptide synthesis (SPPS) of molecular imaging contrast agents. A DO3A moiety was derivatized to introduce a CBZ-protected amino group and then coupled to a polymeric support. CBZ cleavage with Et2AlCl/thioanisole was optimized for SPPS. Amino acids were then coupled to the aminoDOTA-loaded resin using conventional stepwise Fmoc SPPS to create a product with DOTA coupled to the C-terminus of the peptide. In a second study, the DO3A moiety was coupled to a glycine-loaded polymeric support, and amino acids were then coupled to the amino-DOTA-peptide-loaded resin using SPPS to incorporate DOTA within the peptide sequence. The peptide-(Tm3+-DOTA) amide showed a paramagnetic chemical exchange saturation transfer (PARACEST) effect, which demonstrated the utility of this contrast agent for molecular imaging. These results demonstrate the advantages of exploiting SPPS methodologies through development of unique DOTA derivatives to create peptide-based molecular imaging contrast agents.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoo</LastName>
<ForeName>Byunghee</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Case Center of Imaging Research and Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio 44106, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pagel</LastName>
<ForeName>Mark D</ForeName>
<Initials>MD</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P30 DK027651-259018</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R24CA110943</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2007</Year>
<Month>03</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Bioconjug Chem</MedlineTA>
<NlmUniqueID>9010319</NlmUniqueID>
<ISSNLinking>1043-1802</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C493794">1,4,7-tris(tert-butylacetate)-1,4,7,10-tetraazacyclododecane ester</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006573">Heterocyclic Compounds, 1-Ring</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>60239-18-1</RegistryNumber>
<NameOfSubstance UI="C071349">1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>8RKC5ATI4P</RegistryNumber>
<NameOfSubstance UI="D013932">Thulium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Bioorg Med Chem. 1999 Nov;7(11):2313-20</RefSource>
<PMID Version="1">10632041</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bioconjug Chem. 2005 Sep-Oct;16(5):1232-9</RefSource>
<PMID Version="1">16173803</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pept Res. 2000 Apr;55(4):295-9</RefSource>
<PMID Version="1">10798374</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Chemistry. 2001 Jan 5;7(1):288-96</RefSource>
<PMID Version="1">11205022</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bioconjug Chem. 2001 Mar-Apr;12(2):320-4</RefSource>
<PMID Version="1">11312695</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Chemistry. 2001 Dec 3;7(23):5160-7</RefSource>
<PMID Version="1">11775689</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bioconjug Chem. 2002 Mar-Apr;13(2):224-31</RefSource>
<PMID Version="1">11906259</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Chem Soc. 2002 Apr 10;124(14):3514-5</RefSource>
<PMID Version="1">11929234</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Magn Reson Med. 2002 Apr;47(4):639-48</RefSource>
<PMID Version="1">11948724</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Magn Reson Med. 2002 Jun;47(6):1121-30</RefSource>
<PMID Version="1">12111958</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Inorg Biochem. 2002 Jul 25;91(1):320-6</RefSource>
<PMID Version="1">12121791</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bioconjug Chem. 2002 Nov-Dec;13(6):1176-80</RefSource>
<PMID Version="1">12440850</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bioconjug Chem. 2003 Jul-Aug;14(4):715-9</RefSource>
<PMID Version="1">12862423</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Biol Inorg Chem. 2003 Sep;8(7):746-50</RefSource>
<PMID Version="1">14505078</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acc Chem Res. 2003 Oct;36(10):783-90</RefSource>
<PMID Version="1">14567712</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bioconjug Chem. 2003 Nov-Dec;14(6):1177-84</RefSource>
<PMID Version="1">14624632</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Imaging. 2003 Oct;2(4):333-41</RefSource>
<PMID Version="1">14717332</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Chemistry. 2004 Mar 5;10(5):1149-55</RefSource>
<PMID Version="1">15007806</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bioconjug Chem. 2004 Sep-Oct;15(5):1118-24</RefSource>
<PMID Version="1">15366968</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Imaging Biol. 2004 Sep-Oct;6(5):350-9</RefSource>
<PMID Version="1">15380745</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Anal Biochem. 1970 Apr;34(2):595-8</RefSource>
<PMID Version="1">5443684</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Anal Chim Acta. 1972 Jan;58(1):248-9</RefSource>
<PMID Version="1">5057745</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Anal Biochem. 1981 Oct;117(1):147-57</RefSource>
<PMID Version="1">7316187</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Pept Protein Res. 1990 Sep;36(3):255-66</RefSource>
<PMID Version="1">2279849</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pept Res. 1991 Mar-Apr;4(2):88-94</RefSource>
<PMID Version="1">1815782</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pept Res. 1991 Mar-Apr;4(2):95-101</RefSource>
<PMID Version="1">1815783</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bioconjug Chem. 1992 Jul-Aug;3(4):342-5</RefSource>
<PMID Version="1">1390990</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 1998 Dec 4;273(49):32608-13</RefSource>
<PMID Version="1">9829999</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bioorg Med Chem Lett. 1998 May 19;8(10):1207-10</RefSource>
<PMID Version="1">9871736</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bioconjug Chem. 1999 Mar-Apr;10(2):316-20</RefSource>
<PMID Version="1">10077483</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Nucl Med Mol Imaging. 2006 May;33(5):532-40</RefSource>
<PMID Version="1">16491425</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Med Chem. 1999 Jul 29;42(15):2852-61</RefSource>
<PMID Version="1">10425094</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bioorg Med Chem. 1999 Sep;7(9):1797-803</RefSource>
<PMID Version="1">10530927</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Org Chem. 2004 Dec 10;69(25):8821-8</RefSource>
<PMID Version="1">15575763</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2005 May 31;102(22):7976-81</RefSource>
<PMID Version="1">15911748</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Magn Reson. 2000 Mar;143(1):79-87</RefSource>
<PMID Version="1">10698648</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003287">Contrast Media</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000138">chemical synthesis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D003952">Diagnostic Imaging</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006573">Heterocyclic Compounds, 1-Ring</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010455">Peptides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000138">chemical synthesis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D013932">Thulium</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS62000</OtherID>
<OtherID Source="NLM">PMC2584118</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2007</Year>
<Month>3</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2007</Year>
<Month>3</Month>
<Day>3</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2007</Year>
<Month>8</Month>
<Day>30</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2007</Year>
<Month>3</Month>
<Day>3</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1021/bc060250q</ArticleId>
<ArticleId IdType="pubmed">17330953</ArticleId>
<ArticleId IdType="pmc">PMC2584118</ArticleId>
<ArticleId IdType="mid">NIHMS62000</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000626 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000626 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Terre
   |area=    ThuliumV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:17330953
   |texte=   Peptidyl molecular imaging contrast agents using a new solid-phase peptide synthesis approach.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:17330953" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ThuliumV1

This area was generated with Dilib version V0.6.21.
Data generation: Thu May 12 08:27:09 2016. Site generation: Thu Mar 7 22:33:44 2024

	Serveur d'exploration sur le thulium
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le thulium

Peptidyl molecular imaging contrast agents using a new solid-phase peptide synthesis approach.

Peptidyl molecular imaging contrast agents using a new solid-phase peptide synthesis approach.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki